Contracts › 75F40123C00209
75F40123C00209: A Study in Medicare Advantage for Real World Evidence in Cardiovascular Disease
Awarded to Duke University by Food and Drug Administration (FDA).
$1.6Mobligated
$1.6Mpotential value
28 June 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75F40123C00209 |
|---|---|
| Awardee | Duke University |
| Awarding agency | Food and Drug Administration (FDA) |
| Awarding office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN11 Health R&D Services; Health Care Services; Basic Research |
| Place of performance | MD |
| Offers received | 1 |
| Period of performance | 28 September 2023 to 28 June 2027 |
| Potential end | 28 June 2027 |
| Estimated recompete solicitation | ~Q4 2026 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record